Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat

Published 03/02/2023, 16:38
Updated 03/02/2023, 16:38
© Reuters

© Reuters

By Scott Kanowsky 

Investing.com -- Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rose on Friday after the drugmaker posted better-than-expected earnings in the fourth quarter despite a dip in sales of its key eye drug.

The blockbuster medication, known as Eylea, has supported the company's performance since its release over a decade ago. In 2022, it raked in $6.27 billion in sales.

However, the temporary closure of a non-profit fund that provides patient co-pay assistance partly contributed to a 3% decline in sales of Eylea in the final three months of the year to $1.5B. The company noted that customers had also shifted to an off-label brand of Eylea, although this was deemed a "short-term" trend.

The winding down by the U.S. government of a pandemic-era drug procurement program meant that Regeneron did not book any sales from its COVID antibody cocktail as well. In the final quarter of 2021, sales of the therapy had come in at $2.3B.

But strong demand remained for the eczema drug Dupixent, which was recorded in partner Sanofi's (NASDAQ:SNY) results, helped partially offset these drops. Regeneron took home $836M in collaboration revenue from the French pharmaceutical firm, an increase of 61% year-on-year.

"The change in the Company's share of profits from commercialization of antibodies was driven by profits associated with higher Dupixent sales," Regeneron said in a statement.

As a result, total quarterly revenues of $3.4B were above Bloomberg consensus estimates of $3.12B, even though the top-line figure slumped by 31%. Profit of $12.56 per share during the period was also above expectations of $10.03 a share, according to Reuters.

In a note to clients, analysts at RBC Capital Markets said Regeneron's latest numbers were "generally in-line" with prior predictions, but flagged that "shares will likely trade near-term around less predictable Eylea dynamics."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.